NO20012782L - Mikroniserte eplerenon sammensetninger - Google Patents

Mikroniserte eplerenon sammensetninger

Info

Publication number
NO20012782L
NO20012782L NO20012782A NO20012782A NO20012782L NO 20012782 L NO20012782 L NO 20012782L NO 20012782 A NO20012782 A NO 20012782A NO 20012782 A NO20012782 A NO 20012782A NO 20012782 L NO20012782 L NO 20012782L
Authority
NO
Norway
Prior art keywords
micronized eplerenone
compositions
eplerenone compositions
micronized
eplerenone
Prior art date
Application number
NO20012782A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012782D0 (no
Inventor
Shilpa S Thosar
Rajeev D Gokhale
Dwain S Tolbert
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20012782(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO20012782D0 publication Critical patent/NO20012782D0/no
Publication of NO20012782L publication Critical patent/NO20012782L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20012782A 1998-12-09 2001-06-06 Mikroniserte eplerenon sammensetninger NO20012782L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11164698P 1998-12-09 1998-12-09
PCT/US1999/029136 WO2000033847A1 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Publications (2)

Publication Number Publication Date
NO20012782D0 NO20012782D0 (no) 2001-06-06
NO20012782L true NO20012782L (no) 2001-07-03

Family

ID=22339668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012782A NO20012782L (no) 1998-12-09 2001-06-06 Mikroniserte eplerenon sammensetninger

Country Status (30)

Country Link
US (7) US6410054B1 (cs)
EP (1) EP1135139B1 (cs)
JP (1) JP2002531508A (cs)
KR (1) KR100671275B1 (cs)
CN (1) CN1230179C (cs)
AR (1) AR028982A1 (cs)
AT (1) ATE249223T1 (cs)
AU (1) AU763166B2 (cs)
BR (1) BR9915964A (cs)
CA (1) CA2326842A1 (cs)
CZ (1) CZ20011942A3 (cs)
DE (1) DE69911240T2 (cs)
DK (1) DK1135139T3 (cs)
EA (1) EA003266B1 (cs)
ES (1) ES2207977T3 (cs)
HK (1) HK1041641B (cs)
HU (1) HU224428B1 (cs)
ID (1) ID30115A (cs)
IL (1) IL143301A0 (cs)
IS (1) IS2325B (cs)
MY (1) MY125651A (cs)
NO (1) NO20012782L (cs)
NZ (1) NZ511869A (cs)
PL (1) PL198425B1 (cs)
PT (1) PT1135139E (cs)
TR (1) TR200101643T2 (cs)
TW (1) TWI234459B (cs)
UA (1) UA74141C2 (cs)
WO (1) WO2000033847A1 (cs)
ZA (1) ZA200104361B (cs)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ES2240209T3 (es) * 1999-12-08 2005-10-16 Pharmacia Corporation Composiciones de eplerenona nanoparticulada.
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
CA2415789A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
AP2004002951A0 (en) * 2001-07-19 2004-03-31 Pharmacia Corp "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
AU2002249804A1 (en) * 2001-12-13 2003-06-30 Pharmacia Corporation Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
JP2005521665A (ja) * 2002-01-30 2005-07-21 ファルマシア・コーポレーション 心血管障害の予防および治療のための、アルドステロンアンタゴニストおよび非ステロイド系抗炎症剤の併用治療
KR101002374B1 (ko) * 2002-02-26 2010-12-17 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
NZ548754A (en) * 2002-04-26 2008-06-30 Schering Aktiengellschaft Treatment of hypertension in women receiving hormone replacement therapy
AU2003259979A1 (en) * 2002-08-23 2004-03-11 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
ATE454155T1 (de) * 2002-11-05 2010-01-15 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AR044069A1 (es) * 2003-04-25 2005-08-24 Nova Cardia Inc Un metodo de diuresis mejorada en individuos con funcion renal deteriorada
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
EP2535042A1 (en) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Oral sustained-release composition comprising a macrolide
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
PL1663182T5 (pl) * 2003-09-12 2020-07-27 Amgen Inc. Szybko rozpuszczalna formulacja cynakalcetu HCI
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN101094671A (zh) * 2004-04-16 2007-12-26 美国诺华卡迪亚公司 包含腺苷a1受体拮抗剂和醛固酮抑制剂的组合疗法
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
WO2006057501A1 (en) * 2004-11-23 2006-06-01 Dong Wha Pharmaceutical. Ind. Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt
WO2006097342A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process for making steroidal compounds
US20060252738A1 (en) * 2005-05-06 2006-11-09 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070095705A1 (en) * 2005-10-31 2007-05-03 Legault Dennis X Array of packages
JP5030973B2 (ja) * 2006-01-13 2012-09-19 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション あるｉｐｆ（特発性肺線維症）患者が、ｖ型コラーゲンによる経口寛容治療の候補であるかを決定するための方法
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
WO2007102169A1 (en) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
ATE481089T1 (de) * 2006-05-31 2010-10-15 Vertex Pharma Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting- enzyme inhibitors
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
EP2124959A4 (en) * 2006-12-21 2011-09-14 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION
CA2675538C (en) 2007-01-22 2017-02-28 Genpharm Ulc Oral pharmaceutical compositions comprising unmicronized nebivolol or a nebivolol analogue as active ingredient, and a decreased ratio of wetting agent to active ingredient
TW200836774A (en) 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20090232896A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions
US8343524B2 (en) * 2008-07-31 2013-01-01 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
HUE038033T2 (hu) * 2009-08-28 2018-10-29 Hercules Llc Filmbevonó kompozíció szilárd por anyagösszetételekbõl
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
EP2515871B1 (en) 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
CA2802831C (en) * 2010-06-16 2018-11-20 Teijin Pharma Limited Controlled release coat-core tablet
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
KR20120093461A (ko) * 2011-01-27 2012-08-23 양지화학 주식회사 정제형 감미료 조성물 및 그 제조방법
WO2013095311A1 (en) 2011-11-25 2013-06-27 Mahmut Bilgic Inhalation device
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
KR20170091785A (ko) 2012-06-04 2017-08-09 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
FR3001890B1 (fr) * 2013-02-08 2015-08-07 Greenpharma Sas Composition dermatologique pour repousse des poils ou des cheveux
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
US10716783B2 (en) 2013-12-12 2020-07-21 Cornell University Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
FR3019045A1 (fr) * 2014-03-26 2015-10-02 Greenpharma Sas Composition dermatologique pour la repousse des poils ou des cheveux
RU2017106795A (ru) 2014-08-07 2018-09-07 Фармасайкликс Элэлси Новые составы ингибитора тирозинкиназы брутона
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
AU2015377223A1 (en) 2015-01-12 2017-08-31 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
GB201913972D0 (en) * 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082751A (en) * 1976-02-13 1978-04-04 Bristol-Myers Company Therapeutic agents
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4847093A (en) 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NZ238867A (en) 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
WO1992013547A1 (en) 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
GB9311191D0 (en) 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
AU5692398A (en) 1996-12-09 1998-07-03 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
CN100369927C (zh) 1996-12-11 2008-02-20 G·D·瑟尔公司 9,11-环氧甾族化合物和其中有用的中间体的制备方法
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ES2240209T3 (es) * 1999-12-08 2005-10-16 Pharmacia Corporation Composiciones de eplerenona nanoparticulada.

Also Published As

Publication number Publication date
JP2002531508A (ja) 2002-09-24
IS5953A (is) 2001-05-25
KR100671275B1 (ko) 2007-01-19
US20020136775A1 (en) 2002-09-26
AU763166B2 (en) 2003-07-17
BR9915964A (pt) 2001-08-28
HU224428B1 (hu) 2005-09-28
PL198425B1 (pl) 2008-06-30
US20030215518A1 (en) 2003-11-20
CA2326842A1 (en) 2000-06-15
EP1135139B1 (en) 2003-09-10
US20030072808A1 (en) 2003-04-17
US6558707B1 (en) 2003-05-06
AR028982A1 (es) 2003-06-04
PT1135139E (pt) 2004-02-27
CN1230179C (zh) 2005-12-07
US7157101B2 (en) 2007-01-02
ID30115A (id) 2001-11-08
HUP0104718A2 (hu) 2003-01-01
DE69911240D1 (de) 2003-10-16
DE69911240T2 (de) 2004-07-15
HUP0104718A3 (en) 2002-10-28
DK1135139T3 (da) 2004-01-05
NZ511869A (en) 2003-05-30
EP1135139A1 (en) 2001-09-26
AU1936800A (en) 2000-06-26
MY125651A (en) 2006-08-30
HK1041641A1 (en) 2002-07-19
ES2207977T3 (es) 2004-06-01
ATE249223T1 (de) 2003-09-15
ZA200104361B (en) 2002-05-28
IL143301A0 (en) 2002-04-21
IS2325B (is) 2007-12-15
US6863902B2 (en) 2005-03-08
US6534093B1 (en) 2003-03-18
EA003266B1 (ru) 2003-02-27
KR20010101132A (ko) 2001-11-14
US6495165B1 (en) 2002-12-17
WO2000033847A1 (en) 2000-06-15
NO20012782D0 (no) 2001-06-06
UA74141C2 (uk) 2005-11-15
EA200100519A1 (ru) 2002-02-28
US6410054B1 (en) 2002-06-25
HK1041641B (zh) 2006-04-28
TWI234459B (en) 2005-06-21
CN1329494A (zh) 2002-01-02
US20040192661A1 (en) 2004-09-30
CZ20011942A3 (cs) 2001-12-12
TR200101643T2 (tr) 2002-04-22
US6592902B2 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
NO20012782D0 (no) Mikroniserte eplerenon sammensetninger
ATE293977T1 (de) Nanopartikelzusammensetzungen enthaltend eplerenon
DE69903404D1 (de) Celecoxib-Zusammensetzungen
EA199900373A3 (ru) Фармацевтические композиции
DE69933200D1 (de) Kombinierte impfstoffzusammensetzungen
AR023440A1 (es) Composiciones antitranspirantes
ATE367845T1 (de) Riechstoffzusammensetzungen
DE69900634D1 (de) Shampoozusammensetzungen
DE69928933D1 (de) Strahlungshärtbare zusammensetzungen
DE60024826D1 (de) Synergistische insektizide zusammensetzungen
ITMI991754A0 (it) Composizioni cosmetiche
DE60007731D1 (de) Schweisshemmende zusammensetzungen
ATE258418T1 (de) Shampoozusammensetzungen
PT1124567E (pt) Composicoes tamponadas para dialise
NO993460D0 (no) Paroxetine-preparater
FR2787721B1 (fr) Compositions extinctrices
ATE224902T1 (de) Organometallzusammensetzungen
PT1058536E (pt) Composicoes fracamente irritantes
EE200000459A (et) Farmatseutilised kompositsioonid
IT1302028B1 (it) Composizioni espandenti
DE69904800D1 (de) N-Acetonylbenzamide enthaltende fungizide Zusammensetzungen
IT1304174B1 (it) Composizioni perossidiche
SE9800052D0 (sv) Pharmaceutical compositions
FI981567A0 (fi) Farmaseuttiset koostumukset
SE9902635D0 (sv) New compositions